Funds, rolling funds, and active angels writing checks into Raleigh, Durham, Chapel Hill, and RTP startups. Profiles cover thesis, portfolio shape, and deployment cadence where the data is public.
Index fund for NC startups
91 portfolio companies · 12-18 companies/quarter
Healthcare VC with $900M+ under management across 7 funds.
27 companies in the directory
Early-stage venture capital fund.
14 companies in the directory
Venture arm of Duke University, investing in Duke-connected companies from offices in Durham. The portfolio spans consumer, enterprise, and life science nationally; Triangle holdings include Tune Therapeutics, restor3d, Pryon, Teamworks, Vulcan Elements, and Xilis.
12 companies in the directory
Seed stage B2B software in the Southeast. 43+ investments.
9 companies in the directory
B2B software VC. 39 portfolio companies.
8 companies in the directory
Duke Innovation & Entrepreneurship program
7 companies in the directory
Angel network connecting NC State alumni investors with NC State-affiliated startups, run out of the university's Office of Research and Innovation. Members have invested more than $20M since the network's 2016 founding.
6 companies in the directory
Seed-stage therapeutics fund launched 2024.
4 companies in the directory
Grant and investment vehicle for NC startups.
4 companies in the directory
Angel network for the UNC-Chapel Hill community, pairing alumni investors with university-connected startups alongside the Carolina Growth Fund co-investment vehicle.
3 companies in the directory
Early-stage VC focused on digital disruption. 62+ companies.
2 companies in the directory
Strategy and Corporate Development Consultant | Board Member | Investor | Advisor. 25 years of experience, ~$7B in cumulative deal value. Triangle-based individual investor and board/advisor across multiple local software companies. Per-company roles: Scale Social AI — investor (Oct 2025) and advisor; Bull City Venture Partners — investor and advisory board member; Levitate — board member.
2 companies in the directory
Raleigh early-stage venture firm investing in physical and industrial technology across the Southeast, founded 2018. Typical checks run $500K to $1.5M from pre-seed through Series A.
2 companies in the directory
RA Capital Management, L.P. is a Boston-based healthcare and life-sciences crossover investor, founded in 2004 by Vertex co-founder Richard Aldrich, investing across private and public markets. It leads seed and venture rounds, anchors IPOs, and provides follow-on public-market and structured capital. A separate Planetary Health Fund backs climate, minerals, energy, and agriculture companies with near-term commercialization paths. RA Capital pairs capital with in-house company-building teams, including its TechAtlas landscape-mapping engine, the Blackbird clinical-development accelerator, and the Raven biotech incubator. Reported scale: more than 250 employees and over $14B in assets under management. Locally, RA Capital co-led Slate Medicines' $130M Series A launch and participated in Incyclix Bio's Series B.
2 companies in the directory
2 companies in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
Boston-based early-stage venture capital firm, founded 2002. Invests across consumer, enterprise SaaS, and frontier tech.
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
Cary early-stage investment group backing medical technology, industrial technology, clean or green technology, and B2B SaaS companies. Harbright Ventures led SonoVascular's $6M Series A first close in 2026.
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
Angel network in the Research Triangle Park region focused on seed and early-stage, technology-centric companies near revenue.
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
Early-stage venture capital fund focused on Midwest and emerging-market startups (Milwaukee-area lineage; the 414 area code).
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
1 company in the directory
Founder-led pre-seed partnership in Downtown Durham. $5K angel checks plus deal-by-deal SPVs up to $100K. Post-product, often first check in. In-person founder community with office space, founder dinners, GTM workshops, pitch practice, and operator-led tactical sessions.
~10 investments per year · founded April 2026
102-company portfolio. 4 IPOs, 13 acquisitions.
Durham venture capital and commercial development firm focused on life-science, agriculture, and technology companies. The firm operates Pappas Ventures, Specialized Fund Management, and Translational Medicine; Pappas Ventures reports six funds raised, 40 IPO or M&A transactions across the portfolio, four companies sold for $1B or more, and 27 approved products developed by portfolio companies.
93 profiles listed. Tell us if a Triangle-active fund or angel is missing.